VolitionRx (NYSEAMERICAN:VNRX) Stock Passes Below 50-Day Moving Average of $1.86

Shares of VolitionRx Limited (NYSEAMERICAN:VNRX) passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $1.86 and traded as low as $1.24. VolitionRx shares last traded at $1.25, with a volume of 47,276 shares changing hands.

Wall Street Analysts Forecast Growth

VNRX has been the topic of several analyst reports. Cantor Fitzgerald reduced their price target on shares of VolitionRx from $3.00 to $2.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 16th. StockNews.com upgraded shares of VolitionRx to a “sell” rating in a report on Sunday, July 30th.

VolitionRx Stock Performance

The firm has a 50 day simple moving average of $1.86. The firm has a market cap of $78.98 million, a price-to-earnings ratio of -2.23 and a beta of 1.59.

VolitionRx (NYSEAMERICAN:VNRX) last issued its earnings results on Monday, August 14th. The medical research company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). The firm had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.29 million. VolitionRx had a negative return on equity of 15,493.47% and a negative net margin of 9,158.31%. Sell-side analysts predict that VolitionRx Limited will post -0.5 earnings per share for the current year.

Institutional Investors Weigh In On VolitionRx

Institutional investors and hedge funds have recently bought and sold shares of the stock. Creative Planning purchased a new stake in VolitionRx in the fourth quarter valued at $32,000. Dfpg Investments LLC purchased a new stake in shares of VolitionRx in the second quarter valued at about $38,000. Jane Street Group LLC purchased a new stake in shares of VolitionRx in the first quarter valued at about $50,000. Cubist Systematic Strategies LLC purchased a new stake in shares of VolitionRx in the first quarter valued at about $58,000. Finally, JPMorgan Chase & Co. purchased a new stake in shares of VolitionRx in the first quarter valued at about $72,000. 10.14% of the stock is owned by hedge funds and other institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes.